A new dosage form of LG Chem's diabetes combination drug ‘Zemimet SR Tab (gemigliptin /metformin) will be added to the reimbursement list next month.

This is expected to increase prescription options in the field and allow fully personalized prescriptions for the patients.

According to industry sources on the 27th, Zemimet SR Tab 25/750 mg will be added to the reimbursement list from April 1. Zemimet SR Tab 25/750 mg is a combination of 25 mg of gemigliptin and 750 mg of metformin.

The addition of the 25/750mg dose will bring the total lineup of Zemimet SR Tab to five. This is the most diverse array of options provided among all DPP-4 inhibitor class products.